Results 121 to 130 of about 1,056 (174)

Targeting type 2 inflammation in dermatology: mechanisms and clinical implications. [PDF]

Front Immunol
Khalil N, Farhadi L, Yosipovitch G.
europepmc   +1 more source

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation. [PDF]

Allergol Select
Werfel T, Heratizadeh A, Augustin M, Bangert C, Bauer A, Biedermann T, Brans R, Domröse N, Gieler U, Gießler-Fichtner O, Hamelmann E, Hampe S, Heuer R, Kahle J, Kinberger M, Koch M, Köhler M, Legat F, Nemat K, Neustädter I, Peters EMJ, Radonjic-Hoesli S, Reese I, Schmid-Grendelmeier P, Schmidt-Göhrich UK, Schmitt J, Schnopp C, Schwennesen T, Simon D, Stamos K, Termeer C, Treudler R, von Kiedrowski R, Wagner I, Waßmann-Otto A, Weckmann G, Werner RN, Wollenberg A, Worm M, Ott H.   +39 more
europepmc   +1 more source

Convergent Oncostatin M and IL-31 Signaling in Chronic Pruritic Dermatoses: A Neuroimmune Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Perspective. [PDF]

Cureus
Tashjian M, Rankin EK, Tehrani L, Ruppe M, Riskin SI.   +4 more
europepmc   +1 more source

Response to letter from Fontaine et al. [PDF]

JAAD Int
Singh N, Conner A, Nahmias Z.
europepmc   +1 more source

Corrigendum to 'Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab' JID Innovations, Volume 6, Issue 3, May 2026, 100457. [PDF]

JID Innov
Nakajima S, Iizuka H, Taira K, Tanaka K, Hashimoto K, Kaneda N, Iwasaki K, Takafuji T, Yamada Y, Kabashima K.   +9 more
europepmc   +1 more source

Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab. [PDF]

JID Innov
Nakajima S, Iizuka H, Taira K, Tanaka K, Hashimoto K, Kaneda N, Iwasaki K, Takafuji T, Yamada Y, Kabashima K.   +9 more
europepmc   +1 more source

Porokeratosis ptychtropica successfully treated with nemolizumab

JAAD Case Reports
Jerald Sklar, Grace Neill, Alexandria Marrs, Prasana Sinkre   +3 more
openaire   +1 more source

Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials. [PDF]

BMC Med
Zeng L, Zhou T, Zhang L, Xian M, Zhu Z, Liu J, Fu S, Luo H, Li J.   +8 more
europepmc   +1 more source

Literature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents. [PDF]

Clin Cosmet Investig Dermatol
Avriyanti E, Larasati R, Rengasamy S, Hidayah RMN, Tsaqilah L, Pangastuti M, Maharani RH.   +6 more
europepmc   +1 more source

The Absence of Recent Systemic Therapy can be a Significant Risk Factor for Nemolizumab-associated Cutaneous Adverse Events in Patients with Prurigo Nodularis: A Single-centre Retrospective Study

Acta Dermato-Venereologica
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +1 more source